Research Alliance Corporation III Sets $75 Million IPO Pricing as It Targets Healthcare Ventures

Research Alliance Corporation III Announces IPO Pricing

On May 20, 2026, Research Alliance Corporation III (RACC), a special purpose acquisition company, announced the pricing of its initial public offering (IPO) of 7,500,000 Class A shares, valued at $10.00 per share. This pricing signifies a significant move for the company as it gears up to enter the public market, listing on the Nasdaq Capital Market under the ticker symbol "RACC". The shares are set to begin trading on the same day of the announcement, and the company anticipates the offering will close on May 21, 2026, contingent upon customary closing conditions.

Research Alliance Corporation III is sponsored by an affiliate of RA Capital Management, L.P., and is strategically led by CEO Matthew Hammond, PhD, MBA, alongside CBO and COO Henry Stusnick. As a blank check company, RACC's core mission is to pursue mergers or acquisitions, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations. While the scope is broad, RACC specifically aims to focus its acquisition strategy on businesses within the healthcare or healthcare-related industries. The management team believes their extensive expertise in this sector will grant them a competitive edge in successfully completing an initial business combination.

The IPO financing saw participation from numerous institutional investors, including ADAR1 Capital, Affinity Asset Advisors, Balyasny Asset Management, and others, which reinforces the trust in RACC's strategic vision and leadership.

Leerink Partners serves as the sole bookrunning manager for the IPO. Interested investors can acquire further information on the offering through a forthcoming prospectus, which will be available from Leerink Partners LLC, along with contact details for inquiries.

A Look Ahead
The SEC approved the registration statement related to the securities on May 19, 2026, paving the way for RACC's public offering. It’s important to note that this announcement is not an offer or solicitation to buy or sell these securities in jurisdictions where such offers would be unlawful prior to necessary registration or qualification under state or federal laws.

Forward-Looking Statements
This announcement contains forward-looking statements regarding the anticipated completion of the IPO and projected uses for the net proceeds. As with any business venture, there are inherent risks and uncertainties that could affect the realization of expectations outlined in this press release. The risks are detailed in the company's registration statement, which investors can view on the SEC's official website. The company does not intend to update its forward-looking statements unless mandated by law, emphasizing the unpredictable nature of market conditions that could impact their plans.

Overall, Research Alliance Corporation III is poised to take significant steps toward shaping the future of healthcare investments through its strategic public offering. The firm’s focus on healthcare-related enterprises aligns with growing market demands and reflects a stronger emphasis on innovations aiming to enhance health outcomes across various sectors.